Cargando…
Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients
BACKGROUND: Ischemic changes in the retinal circulation are an uncommon but severe adverse vascular reaction to intravitreal bevacizumab (Avastin(®), Genentech, San Francisco, CA, USA/Roche, Basel, Switzerland) for central retinal vein occlusion (CRVO). In the two cases reported here, ischemic chang...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589185/ https://www.ncbi.nlm.nih.gov/pubmed/23467497 http://dx.doi.org/10.2147/OPTH.S30156 |
_version_ | 1782261695919423488 |
---|---|
author | Isola, Vincenzo Pece, Alfredo Massironi, Claudio Reposi, Simone Dimastrogiovanni, Fabio |
author_facet | Isola, Vincenzo Pece, Alfredo Massironi, Claudio Reposi, Simone Dimastrogiovanni, Fabio |
author_sort | Isola, Vincenzo |
collection | PubMed |
description | BACKGROUND: Ischemic changes in the retinal circulation are an uncommon but severe adverse vascular reaction to intravitreal bevacizumab (Avastin(®), Genentech, San Francisco, CA, USA/Roche, Basel, Switzerland) for central retinal vein occlusion (CRVO). In the two cases reported here, ischemic changes in the retina vasculature following intravitreal bevacizumab for CRVO were observed with the aim of describing the clinical and angiographic features of these changes. METHODS: Two elderly patients with recent-onset CRVO received one off-label intravitreal injection of bevacizumab 0.05 mL/1.25 mg. RESULTS: In Case 1, the patient’s pre-treatment visual acuity was 20/400. At 3 weeks post injection, the patient could count fingers at a distance of 1 ft (30 cm) and fluorescein angiography showed reduction in intraretinal hemorrhages and areas of retinal non-perfusion. However, at 6 weeks these were markedly increased compared with those seen in the photograph taken 3 weeks after treatment. In Case 2, the patient’s pre-treatment visual acuity was 20/200. At 1 month post injection, vision had decreased to 20/400 and fluorescein angiography showed severe macular ischemia with a remarkable capillary dropout throughout the macula. CONCLUSION: Ischemic retinal injury may be an uncommon but severe adverse vascular reaction to intravitreal bevacizumab for CRVO. Although progression of retinal ischemia in CRVO could be observed shortly after intravitreal bevacizumab, whether this is a drug- or procedure-related effect or part of the natural history of the condition remains uncertain. |
format | Online Article Text |
id | pubmed-3589185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-35891852013-03-06 Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients Isola, Vincenzo Pece, Alfredo Massironi, Claudio Reposi, Simone Dimastrogiovanni, Fabio Clin Ophthalmol Case Report BACKGROUND: Ischemic changes in the retinal circulation are an uncommon but severe adverse vascular reaction to intravitreal bevacizumab (Avastin(®), Genentech, San Francisco, CA, USA/Roche, Basel, Switzerland) for central retinal vein occlusion (CRVO). In the two cases reported here, ischemic changes in the retina vasculature following intravitreal bevacizumab for CRVO were observed with the aim of describing the clinical and angiographic features of these changes. METHODS: Two elderly patients with recent-onset CRVO received one off-label intravitreal injection of bevacizumab 0.05 mL/1.25 mg. RESULTS: In Case 1, the patient’s pre-treatment visual acuity was 20/400. At 3 weeks post injection, the patient could count fingers at a distance of 1 ft (30 cm) and fluorescein angiography showed reduction in intraretinal hemorrhages and areas of retinal non-perfusion. However, at 6 weeks these were markedly increased compared with those seen in the photograph taken 3 weeks after treatment. In Case 2, the patient’s pre-treatment visual acuity was 20/200. At 1 month post injection, vision had decreased to 20/400 and fluorescein angiography showed severe macular ischemia with a remarkable capillary dropout throughout the macula. CONCLUSION: Ischemic retinal injury may be an uncommon but severe adverse vascular reaction to intravitreal bevacizumab for CRVO. Although progression of retinal ischemia in CRVO could be observed shortly after intravitreal bevacizumab, whether this is a drug- or procedure-related effect or part of the natural history of the condition remains uncertain. Dove Medical Press 2013 2013-03-01 /pmc/articles/PMC3589185/ /pubmed/23467497 http://dx.doi.org/10.2147/OPTH.S30156 Text en © 2013 Isola et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Case Report Isola, Vincenzo Pece, Alfredo Massironi, Claudio Reposi, Simone Dimastrogiovanni, Fabio Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients |
title | Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients |
title_full | Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients |
title_fullStr | Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients |
title_full_unstemmed | Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients |
title_short | Accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients |
title_sort | accelerated ischemic vascular retinopathy after intravitreally injected bevacizumab for central retinal vein occlusion in elderly patients |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589185/ https://www.ncbi.nlm.nih.gov/pubmed/23467497 http://dx.doi.org/10.2147/OPTH.S30156 |
work_keys_str_mv | AT isolavincenzo acceleratedischemicvascularretinopathyafterintravitreallyinjectedbevacizumabforcentralretinalveinocclusioninelderlypatients AT pecealfredo acceleratedischemicvascularretinopathyafterintravitreallyinjectedbevacizumabforcentralretinalveinocclusioninelderlypatients AT massironiclaudio acceleratedischemicvascularretinopathyafterintravitreallyinjectedbevacizumabforcentralretinalveinocclusioninelderlypatients AT reposisimone acceleratedischemicvascularretinopathyafterintravitreallyinjectedbevacizumabforcentralretinalveinocclusioninelderlypatients AT dimastrogiovannifabio acceleratedischemicvascularretinopathyafterintravitreallyinjectedbevacizumabforcentralretinalveinocclusioninelderlypatients |